NCT04221945 2026-02-20KEYNOTE-A18Merck Sharp & Dohme LLCPhase 3 Completed1,060 enrolled 30 charts 1 FDA
NCT03635567 2026-02-04KEYNOTE-826Merck Sharp & Dohme LLCPhase 3 Completed617 enrolled 29 charts 1 FDA
NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled